Nav: Home

Benefits of higher doses of certain medicines fail to justify costs and risks, study shows

May 05, 2020

PORTLAND, Ore. - Clinical trial data behind drug dose recommendations for elevated cholesterol and chronic obstructive pulmonary disease illustrate how larger doses may not be worth the extra costs for many types of patients, according to an Oregon State University College of Pharmacy researcher.

The findings, published in the Journal of American Biomedical Science & Research, point out the need for patients and prescribers to probe as deeply as possible the data behind the medicines we use.

"Drug manufacturers will continue to set prices to what the market will bear," said Craig Williams of the OSU College of the Pharmacy. "Part of what that means is the burden for improving health outcomes rests with all of us as we continue to struggle with the costs of our free-market health care system."

Williams looked at the data used in developing medical recommendations for higher than average doses of statins, used for lowering cholesterol, and long-acting inhalers that treat chronic obstructive pulmonary disease, or COPD.

Six years ago, the national cholesterol guidelines underwent marked changes, Williams said, with the new primary recommendation calling for high doses of statins whenever possible in patients deemed high risk to suffer a cardiovascular event.

The new guidelines were based on five trials that directly compared average doses to higher doses; each trial was partly or wholly sponsored by the makers of the drugs being tested.

"Compared to average doses, higher doses did reduce cardiovascular events - heart attack, stroke or cardiovascular death," said Williams, who has an adjunct faculty appointment at Oregon Health & Science University. "But the percentage reduction across those five trials was 0.4% per year. Put another way, that means 250 patients would need to be treated with high doses for a year so one patient could avoid a cardiovascular event."

Stretching the numbers over a decade, the benefit increases to 4%.

"But based on the math, that still means 25 patients need to take those higher doses for 10 years for one cardiovascular event to be avoided," Williams said. "That might strike you as out of line, or it may seem reasonable. But either way, if you're one of those patients or one of those prescribers, it's pretty important to understand the numbers and not just operate under the principle of 'guidelines recommend higher doses.'"

Like elevated cholesterol, COPD is a commonly treated condition in primary care settings. Since 2017, international guidelines have called for combining two long-acting inhaled therapies as the disease progresses.

"Again, the basis for the recommendation is primarily trials sponsored by the manufacturers of the drugs being prescribed," Williams said.

In one of the largest trials, the combination of two inhaled drugs reduced exacerbations of COPD compared to either drug by itself.

"But exacerbations were defined as a combination of severe, moderate and mild - with mild not requiring any medical intervention," Williams said. "Almost all of the benefit was on mild exacerbations, with no reduction in severe exacerbations."

Again, Williams looks to the numbers as a framework for analysis.

"The reduction in mild exacerbations was 0.5% per year, which means that 200 patients would need to be treated for one year for one less mild exacerbation to occur," he said. "That small magnitude of benefit is not addressed in the guidelines, and an increase in drug use may increase the chance of adverse effects without a meaningful improvement in patient health."

There are also economics to consider, Williams notes. Statins are inexpensive; inhaled therapy for COPD is costly.

"The average cost in the U.S. of long-acting inhaled therapies for COPD is about $400 per month," he said. "That means dual bronchodilator therapy for a patient costs an extra $400 per month or $4,800 per year. Many similar examples of the data behind current drug use can be cited - in some cases the benefit of increased drug therapy is greater than these examples, in other case it's less."

Williams calls attention to statistics provided by the Centers for Disease Control and Prevention, which show that 3.7 billion prescription drugs were used in 2016 and about 12 percent of Americans used five or more prescription drugs.

"In 2015, retail drugs costs rose above $1,000 per person in the U.S. for the first time," he said. "That's between 30% and 190% higher than nine comparable countries."

There are many reasons for the increasing use of prescription drugs in the United States, Williams said. Patients want to take certain drugs. Drug manufacturers are active advertisers, often in misleading ways. Professional societies offer recommendations for drug use that are narrowly focused, often fail to fully explain risk/reward and seldom consider financial costs.

"And then the regulatory agencies that review drugs for market approval don't consider cost effectiveness and offer little guidance on appropriate use after the drug is approved," he said. "Those agencies really should consider the magnitude of benefits and, along with professional societies, do a better job communicating that, as well as the cost effectiveness of their recommendations and approvals."
-end-


Oregon State University

Related Prescription Drugs Articles:

One quarter of prescription drugs in Canada may be in short supply
Research from the Centre for Health Evaluation and Outcome Sciences (CHÉOS) sheds new light on the factors behind drug shortages in Canada, a common problem across the country.
Prescription opioid use, misuse among cancer survivors
This survey study looked at the frequency of prescription opioid use and misuse among adult cancer survivors compared with individuals without cancer.
Medicare Part D favors generic prescription drugs over branded counterparts, study finds
Published this week in Health Affairs, the study led by Stacie Dusetzina, PhD, Ingram Associate Professor of Cancer Research and associate professor of Health Policy, compared Medicare Part D coverage of more than 1,360 pairs of generic and brand-name drugs.
Regular use of prescription drugs for pain and sleep increases frailty risk by 95 percent
Regular use of prescription drugs for pain and sleep increases frailty risk by 95 percent among older adults.
ACP issues policy recommendations aimed at mitigating the rising costs of prescription drugs
In two new policy papers, the American College of Physicians (ACP) calls for changes aimed at mitigating the rising cost of prescription drugs.
Codeine misuse in Australia reduced by prescription-only changes
The move to prescription-only codeine in Australia has seen a 50 percent reduction in the monthly rate of codeine-related poisoning calls and halved codeine sales, finds new research led by the University of Sydney.
Nearly 1 in 3 patients with lupus use prescription opioids for pain
A new study finds nearly one in three adults with lupus use prescription opioids to manage pain, despite a lack of evidence that opioids are effective for reducing pain from rheumatic diseases.
Negotiation: A three-step solution to affordable prescription drugs
Criteria are offered by Harvard University and George Mason University experts for Medicare to negotiate drug prices and prioritize specific drugs for maximum savings.
Prescription drug monitoring program mandates
States that require prescribers to register with and use prescription drug monitoring programs in most clinical circumstances saw notably fewer opioid prescriptions and reduced opioid-related hospital use by Medicaid patients compared to states with weak or no drug monitoring program mandates, according to a new study from investigators at Weill Cornell Medicine.
One-third of pre-approved prescription drugs have not completed the FDA approval process
The Food and Drug Administration's (FDA) Accelerated Approval Program was created in 1992 to significantly accelerate the ability to bring certain new drugs to market.
More Prescription Drugs News and Prescription Drugs Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.